News | Cardiac Resynchronization Therapy Devices (CRT) | May 13, 2020

Left Bundle Branch Pacing is Feasible as a Novel Strategy For Cardiac Resynchronization Therapy

Results from the International LBBP Collaborative Study Group provides remarkably low and stable pacing thresholds for CRT

Left bundle branch (LBBP) activation imaging shown using wall motion color codes on echo imaging from Canon. #HRS2020 #heartrhythm2020

Left bundle branch (LBBP) activation imaging shown using wall motion color codes on dyamic echo imaging from Canon. 

May 13, 2020 — Cardiac resynchronization therapy (CRT) using biventricular pacing (BVP) or His bundle pacing (HBP) is effective in patients with heart failure (HF), bundle branch block or RV pacing. Intraseptal left bundle branch pacing (LBBP) has been reported as an alternative option for CRT and the aim of this late-breaking trial presented at the Heart Rhythm Society (HRS) 2020 Science virtual meeting was to assess the feasibility and outcomes of LBBP in CRT candidates in an international, multicenter, collaborative study.

The study found LBBP is feasible, safe and provides an alternative option for cardiac resynchronization therapy. Researchers said the LBBP provides remarkably low and stable pacing thresholds. Insights from this study may provide better electrophysiologic understanding of LBBP and its role in CRT. The study was presented by Pugazhendhi Vijayaraman, M.D., FHRS, Geisinger Heart Institute, Mountain Top, Penn. 

In the study, LBBP was attempted in patients with LVEF<50% and indications for CRT/pacing at eight international centers. Indications, procedural and pacing parameters, NYHA class, HF hospitalization, echocardiographic data and lead complications were assessed. LBBP was performed as a rescue or primary approach to achieve CRT utilizing SelectSecure 3830 pacing lead. LBB capture was assessed by the presence of: LBB potentials, paced RBBB morphology, nonselective (NS) to selective (S) or myocardial capture, peak LV activation time (pLVAT)<90ms in V6, response to programmed stimulation.

LBBP was attempted in 325 patients and CRT was successfully achieved in 277 (85%); failure due to incomplete CRT 27, failed deep septal deployment 21. Age 71±13 yrs, female 37%, HTN 68%, DM 38%, CAD 47%. Ischemic CMP 36%, nonischemic CMP 59%; LVEF <35% in 65% pts. QRS morphology at baseline: LBBB 42%, RBBB 18%, IVCD 12%, RVP 13%, narrow 16%. Procedure and fluoroscopy duration were 105±54 and 19±16 min. LBBP threshold and R-wave amplitudes were 0.76±[email protected] and 11.5±6.8mV at implant and remained stable during mean f/u of 6±5 months. LBBP resulted in significant narrowing of QRS from 156±32ms to 137±22ms (p<0.0001) with pLVAT of 83±16ms. EF improved from 32±9 to 44±11% (p<0.0001). LBB capture evidence, echo and clinical outcomes and complications will be presented.

The researchers said randomized, controlled trials comparing conduction system pacing to BVP will be necessary to show further proof of concept.

Find links to all the Heart Rhythm Society 2020 Late-Breaking Clinical Trials in Electrophysiology

Related Content

Valentina Kutyifa, M.D., Ph.D., University of Rochester Medical Center, Rochester, N.Y., is doing research in the BIO-LIBRA Study to determine it ICD or CRT-D devices work better in men or women with heart failure often present with non-ischemic cardiomyopathy.

Valentina Kutyifa, M.D., Ph.D., University of Rochester Medical Center, Rochester, N.Y., is doing research in the BIO-LIBRA Study to determine it ICD or CRT-D devices work better in men or women with heart failure often present with non-ischemic cardiomyopathy.

Feature | Cardiac Resynchronization Therapy Devices (CRT) | March 09, 2020 | Valentina Kutyifa M.D., Ph.D.
Cardiovascular disease is the leading cause of death for women in North America, and women with...
His Corrective Pacing Effective as an Initial Strategy for Heart Failure Cardiac Resynchronization CRT therapy vs. biventricular pacing (BiV) as a first-line strategy. #HRS #HRS19 #HRS2019
News | Cardiac Resynchronization Therapy Devices (CRT) | May 15, 2019 | Dave Fornell, Editor
May 15, 2019 — A pilot trial has shown His pacing in...
Biotronik Launches Acticor DX and CRT-DX Devices in U.S.
News | Cardiac Resynchronization Therapy Devices (CRT) | April 29, 2019
Biotronik announced the full commercial launch of the Acticor device family, including Acticor DX and CRT-DX devices....
Biotronik Launches Acticor and Rivacor ICD and CRT-D Devices in Europe
News | Cardiac Resynchronization Therapy Devices (CRT) | April 18, 2019
Biotronik announced the European market release of what it calls the world’s smallest implantable cardioverter...
Medtronic AdaptivCRT Feature Associated with Improved Heart Failure Patient Survival
News | Cardiac Resynchronization Therapy Devices (CRT) | May 22, 2018
Medtronic plc announced study results showing its AdaptivCRT algorithm is associated with improved patient survival....
Medtronic Recalls CRT-Ds and ICDs Due to Manufacturing Error Preventing Electrical Shock Delivery
News | Cardiac Resynchronization Therapy Devices (CRT) | February 26, 2018
The U.S. Food and Drug Administration (FDA) announced that Medtronic is recalling certain implantable cardioverter...
Abbott Announces MR-Conditional Labeling for Quadra Assura CRT-D and Fortify Assura ICD
Technology | Cardiac Resynchronization Therapy Devices (CRT) | January 03, 2018
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT) | August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT) | July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...